Cervical cancer has been one of the most preventable cancers, yet it continues to claim hundreds of thousands of lives around the world every year. Nearly every case is linked to persistent infection with high-risk strains of the human papillomavirus (HPV), a virus so common that most sexually active people will encounter it at some point in their lives. While most infections clear naturally, some persist and can eventually trigger cancerous changes.
The introduction of the HPV vaccine marked a major step forward in cancer prevention. Researchers have long known that vaccination dramatically reduces HPV infections and precancerous cervical changes. More recently, studies have shown significant drops in cervical cancer diagnoses among vaccinated populations. Now, researchers have reached another milestone: they have found compelling evidence that the vaccine is also preventing deaths from cervical cancer.
The First National Evidence That HPV Vaccination Saves Lives
Since England introduced routine HPV vaccination for girls in 2008, researchers have closely tracked its effects. The vaccine was initially offered to girls aged 12 and 13, with catch-up programs extending eligibility to older teenagers. Vaccination rates remained remarkably high, reaching approximately 80 to 90 percent before the COVID-19 pandemic.
To understand whether vaccination affected survival, researchers analyzed cervical cancer mortality records from 2001 through 2024, comparing death rates before and after the vaccination program while accounting for vaccine coverage across different birth cohorts. This is one of the first large-scale studies to examine mortality rather than simply infection rates or cancer diagnoses.
The results were extraordinary.
Among women aged 20 to 24 between 2020 and 2024, researchers expected approximately 23 cervical cancer deaths based on historical trends. Instead, they observed none. Not a single vaccinated woman in that age group died from cervical cancer during the five-year period. Statistical analysis estimated a 100 percent reduction in mortality among women vaccinated at ages 12 to 13, although researchers note that confidence intervals reflect the relatively small number of deaths expected in this young population.
The benefits extended beyond the youngest participants.
Women vaccinated during catch-up campaigns also experienced substantial reductions in cervical cancer mortality. Those vaccinated later in adolescence still showed markedly lower death rates than women who had never been eligible for vaccination. Overall, investigators estimated that England’s HPV vaccination program has already prevented approximately 200 cervical cancer deaths through the end of 2024, with many more lives expected to be saved as vaccinated generations continue to age.
Why Timing Makes the HPV Vaccine So Effective
One of the most important lessons from this research is that when the HPV vaccine is given matters just as much as receiving it. The strongest protection was seen in women who were vaccinated at 12 or 13 years of age, before they had any likely exposure to HPV. At this stage, the immune system produces a powerful response to the vaccine, allowing the body to recognize and stop the virus if it is encountered later in life.
HPV is primarily spread through intimate skin-to-skin contact. Because most infections occur soon after people become sexually active, vaccination works best when it is administered before exposure. The vaccine cannot eliminate an existing HPV infection, but it can prevent infection with the high-risk strains responsible for the vast majority of cervical cancers.
For many people, HPV infection causes no symptoms and disappears on its own within a couple of years. The immune system successfully clears about 90% of infections without causing lasting harm. The remaining infections can persist for years, allowing the virus to interfere with normal cell growth. Over time, these abnormal cells may progress from precancerous changes to invasive cervical cancer if they are not detected and treated.
This long timeline is one reason cervical cancer is considered highly preventable. Vaccination blocks the infection at its earliest stage, while regular cervical screening identifies abnormal cells before they become cancerous. Together, these approaches interrupt the disease long before symptoms appear.
HPV Is Linked to More Than Cervical Cancer
Although this study focused on cervical cancer mortality, the benefits of HPV vaccination extend much further.
High-risk HPV strains are responsible for nearly all cervical cancers, but they are also associated with cancers affecting the vagina, vulva, anus, penis, and parts of the head and neck, including the throat and mouth. Certain HPV types also cause the majority of genital warts. By preventing infection with these virus strains, vaccination lowers the risk of several diseases that may develop years or even decades after the initial exposure.
This broader protection is one reason many countries now recommend HPV vaccination for both girls and boys. Vaccinating boys not only helps protect them against HPV-related cancers but also reduces transmission of the virus throughout the population. As more people become immunized, fewer opportunities remain for HPV to spread, increasing protection even for those who cannot receive the vaccine.
Even with these encouraging results, vaccination should not replace routine cervical screening. No vaccine protects against every cancer-causing HPV strain, and screening remains an essential tool for detecting abnormal cervical cells before they become dangerous. When vaccination and screening are used together, they provide the strongest defense against cervical cancer throughout adulthood
Keep the Momentum Going
England’s results are promising, but progress depends on maintaining high vaccination rates.
HPV vaccine uptake has dropped since the COVID-19 pandemic—from about 90% to roughly 75% in England, with lower rates in some areas. If this trend continues, preventable cancers and deaths could rise again.
Restoring vaccination levels could prevent hundreds of future deaths. Public confidence and access remain key. The HPV vaccine has a strong safety record and provides lasting protection against the strains most likely to cause cancer.
Adults who missed vaccination may still benefit—check with a healthcare provider. And vaccination doesn’t replace screening. Regular cervical screening remains essential for early detection.
These results show what’s possible when vaccination and screening work together—but only if participation stays high.
My Personal RX on Protecting Yourself Against HPV-Related Cancers
Prevention works best when it starts early and stays consistent. Alongside vaccination and screening, daily habits support long-term health and help your body respond more effectively to infections over time.
- Stay up to date on vaccines: Get the HPV vaccine at the recommended age, ideally before any exposure to the virus. If you missed it earlier in life, talk with your healthcare provider about whether vaccination may still benefit you.
- Keep up with screening: Regular cervical screening is still essential, even if you’ve been vaccinated. Screening can detect early cell changes long before they become cancerous, allowing for simple and effective treatment.
- Eat a nutrient-rich diet: Focus on whole foods like vegetables, fruits, healthy fats, and lean proteins. Nutrients such as vitamins A, C, D, and zinc play important roles in supporting immune function and cellular health.
- Prioritize sleep: Aim for consistent, quality rest. Sleep is when your body repairs tissues, regulates hormones, and strengthens immune defenses.
- Avoid smoking: Tobacco increases cancer risk and makes it harder for your body to clear HPV infections. Quitting smoking is one of the most powerful steps you can take for long-term health.
- Stay active: Regular movement supports circulation, immune health, and hormone balance. Even moderate activity, like walking, can make a meaningful difference.
- Practice informed sexual health: Using protection and having open conversations with partners can reduce HPV transmission risk and encourage preventive care.
Sources:
- Sasieni, P., & Milena Falcaro. (2026). Cervical cancer mortality trends following HPV vaccination in England, 2001–24: an analysis of population-based mortality data. The Lancet. https://doi.org/10.1016/s0140-6736(26)00918-9
Subscribe to Ask Dr. Nandi YouTube Channel
